RNase Inhibitor
| Catalog No. | ON-039 |
| Purity | ＞95% by SDS-PAGE |
| Storage Condition | -20℃ |
| Source | Recombinant E.coli |
RNase Inhibitor
RNase Inhibitor - M (Molecular Biology) / Non-GMP / 40kU / centrifuge tube is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Related Products
-
Catalog No.: ON-004-C050
Purity: ＞95% by SDS-PAGE
Source: Recombinant E.coli
From$25.00From $0.00Unit price /Unavailable -
M-MLV Reverse Transcriptase, RNase H Minus
Catalog No.: ON-047
Purity: ＞95% by SDS-PAGE
Source: Recombinant E.coli
Price Inquiry
$0.00Unit price /Unavailable -
M-MLV Reverse Transcriptase, RNase H Plus
Catalog No.: ON-076
Purity: ＞95% by SDS-PAGE
Source: Recombinant E.coli
Price Inquiry
$0.00Unit price /Unavailable
Details
Details
Product Information
Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.
Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.
Key points of operation
- Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
- Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).
Specifications
Specifications
-
Catalog No.ON-039ON-039-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Documentation
Documentation
Product Information
Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.
Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.
Key points of operation
- Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
- Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).
-
Catalog No.ON-039ON-039-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Integrated Supply & Commercial Scale
With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.
